Parameters associated with patient outcomes in lymph node positive prostate cancer

NewsGuard 100/100 Score

Dr. Hofer and colleagues report in the June issue of Urology that lymphovascular invasion (LVI) and the nuclear grade of the primary prostate tumor are independent predictors of PSA recurrence in men with lymph node positive CaP.

The retrospective study included 119 eligible men with lymph node positive CaP who underwent radical prostatectomy at the University of Ulm Hospital, Germany. Clinical and pathologic examination was performed.

The mean number of lymph nodes removed was 12 and the mean number positive was 3. Almost 50% of men had only 1 positive node, 22% had 2 and 34% had more than 2 positive nodes. PSA failure occurred n 41% of these men, leaving 59% free of disease with a mean follow-up of 41 months. The 5-year PSA failure-free survival rate was 61% and the mean PSA failure-free survival time was 54 months.

The metastatic growth pattern in the lymph nodes was similar to the architectural growth pattern used for grading the primary tumor. Extra-nodal extension was seen in 55% of the cases, and 25% had lymph nodes with LVI.

Pre-operative PSAS was not predictive of a PSA failure. However, multivariable analysis demonstrated that LVI of the metastasis and nuclear tumor grade were associated with PSA recurrence. These pathologic parameters may help to identify patients at risk for disease recurrence and direct them towards adjuvant therapies and clinical trials.

By Christopher P. Evans, MD


Reference:

Urol 2006;67:1016-1021

http://www.ncbi.nlm.nih.gov/entrez/

Hofer MD, Kuefer R, Huang W, Li H, Bismar TA, Perner S, Hautmann RE, Sanda MG, Gschwend JE, Rubin MA

UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
First UK real-world study shows promise for sacituzumab govitecan in metastatic breast cancer